Hangzhou Diagens Biotechnology Co., Ltd. (HKG:2526)
Hong Kong · Delayed Price · Currency is HKD 323.80
+36.80 (12.82%)
Jul 31, 2026, 4:08 PM HKT
HKG:2526 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Cash & Equivalents | 12.87 | 17.1 | 20.42 |
Short-Term Investments | 21.59 | 25 | 24.12 |
Trading Asset Securities | 11 | 16.5 | 39.99 |
Cash & Short-Term Investments | 45.46 | 58.6 | 84.53 |
Cash Growth | -22.42% | -30.67% | - |
Accounts Receivable | 53.02 | 32.4 | 6.19 |
Other Receivables | 0.59 | 0.12 | 3.96 |
Receivables | 53.61 | 32.52 | 10.15 |
Inventory | 22.66 | 22.86 | 27.06 |
Prepaid Expenses | 0.81 | 0.35 | 1.04 |
Other Current Assets | 13.41 | 8 | 7.83 |
Total Current Assets | 135.95 | 122.33 | 130.6 |
Property, Plant & Equipment | 29.32 | 37.24 | 35.04 |
Long-Term Investments | 42.93 | 42.9 | 43 |
Other Intangible Assets | 1.66 | 1.1 | 1.63 |
Long-Term Accounts Receivable | 0.16 | 0.04 | - |
Other Long-Term Assets | 5.56 | 8.86 | 10.82 |
Total Assets | 215.58 | 212.47 | 221.09 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Accounts Payable | 17.33 | 7.43 | 3.24 |
Accrued Expenses | 10.76 | 6.5 | 11.06 |
Current Portion of Long-Term Debt | - | 10 | - |
Current Portion of Leases | 1.47 | 2.84 | 3.39 |
Current Income Taxes Payable | 0.01 | - | - |
Current Unearned Revenue | 0.57 | 0.99 | 3.7 |
Other Current Liabilities | 15.02 | 4.1 | 2.3 |
Total Current Liabilities | 45.16 | 31.85 | 23.69 |
Long-Term Leases | 4.45 | 6.28 | 1.11 |
Long-Term Deferred Tax Liabilities | 0.25 | 0.16 | 0.08 |
Other Long-Term Liabilities | - | - | 281.83 |
Total Liabilities | 49.85 | 38.29 | 306.71 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Common Stock | 80.88 | 20.88 | 20.88 |
Retained Earnings | -198.68 | -272.08 | -228.7 |
Comprehensive Income & Other | 283.53 | 425.38 | 122.2 |
Shareholders' Equity | 165.73 | 174.18 | -85.62 |
Total Liabilities & Equity | 215.58 | 212.47 | 221.09 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Total Debt | 5.92 | 19.12 | 4.5 |
Net Cash (Debt) | 39.54 | 39.48 | 80.03 |
Net Cash Growth | 0.16% | -50.67% | - |
Net Cash Per Share | 0.49 | 0.50 | 1.05 |
Filing Date Shares Outstanding | 88.88 | 80.88 | 76.18 |
Total Common Shares Outstanding | 80.88 | 80.88 | 76.18 |
Working Capital | 90.8 | 90.48 | 106.91 |
Book Value Per Share | 2.05 | 2.15 | -1.12 |
Tangible Book Value | 164.06 | 173.08 | -87.24 |
Tangible Book Value Per Share | 2.03 | 2.14 | -1.15 |
Machinery | 30.31 | 31.79 | 24.34 |
Leasehold Improvements | 9.68 | 16.01 | 16.76 |